The upcoming 13th ministerial conference of the World Trade Organization in Geneva seems to be becoming an event focused on deferring critical issues previously agreed upon during the MC12 ministerial meeting held in July 2022, according to informed sources.
Recent developments within the WTO's Trade-Related Aspects of Intellectual Property Rights Council indicate that there will be no decision to extend the TRIPS-partial waiver to COVID-19 diagnostics and therapeutics.
Similarly, the sixth draft of the ministerial decision on dispute settlement reform, particularly regarding the appeal review mechanism, suggests that the two-tier dispute settlement system, considered the "jewel in the crown," will not be reinstated at MC13, despite the mandate provided in MC12.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
If you are a current subscriber, and had an account on our previous site, you already have an account. If you have not yet logged into our new site, click here to reset your password.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
